|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
The effect of SEMA3C knockdown on cancer cells was determined using in vitro cellular function assays.
|
26977026 |
2016 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Overall, our findings demonstrate that aberrant expression of sema3c is correlated with poor prognosis of PDAC patients and promotes tumor growth and metastasis by activating ERK1/2 signaling pathway.
|
28315433 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis.
|
25808871 |
2015 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that SEMA3C expression is differentially regulated in the development and progression of breast versus oral neoplasia, and that increased expression of SEMA3C may be modulating breast cancer progression and angiogenesis, and could represent a biomarker of metastatic disease.
|
25910410 |
2015 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Recent studies suggested involvement of Sema3C (semaphorin 3C) protein in tumorigenesis and metastasis in a number of cancers.
|
26032848 |
2015 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Previous studies have suggested that semaphorin 3C (SEMA3C) is involved in the tumorigenesis and metastasis of a number of types of cancer.
|
29113226 |
2017 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
In particular, we summarize SEMA3C's role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach.
|
30759745 |
2019 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration <i>in vivo</i> SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.
|
29348142 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Semaphorin 3C (SEMA3C) is a secreted signaling protein with roles in nervous system and cardiac development but can also drive cellular growth and invasive characteristics in multiple cancers including PCa.
|
28038451 |
2017 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Expression of Sema3C was upregulated and Sema3A and Sema3E were down regulated in prostate cells by hypoxia, consistent with an additional role for Sema3A and 3E as anti-angiogenic factors in prostate cancer.
|
20949546 |
2011 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Given SEMA3C's roles in development and its augmented expression in PCa, we hypothesized that SEMA3C promotes epithelial-to-mesenchymal transition (EMT) and stem-like phenotypes in prostate cells.
|
28904399 |
2017 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Semaphorin 3C (SEMA3C) is a secreted signaling protein with roles in nervous system and cardiac development but can also drive cellular growth and invasive characteristics in multiple cancers including PCa.
|
28038451 |
2017 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In particular, we summarize SEMA3C's role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach.
|
30759745 |
2019 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Given SEMA3C's roles in development and its augmented expression in PCa, we hypothesized that SEMA3C promotes epithelial-to-mesenchymal transition (EMT) and stem-like phenotypes in prostate cells.
|
28904399 |
2017 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Expression of Sema3C was upregulated and Sema3A and Sema3E were down regulated in prostate cells by hypoxia, consistent with an additional role for Sema3A and 3E as anti-angiogenic factors in prostate cancer.
|
20949546 |
2011 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration <i>in vivo</i> SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.
|
29348142 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients.
|
12174914 |
2002 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Inhibition of SEMA3C reduces adhesion and invasion of breast cancer cells.
|
26977026 |
2016 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data suggest that SEMA3C expression is differentially regulated in the development and progression of breast versus oral neoplasia, and that increased expression of SEMA3C may be modulating breast cancer progression and angiogenesis, and could represent a biomarker of metastatic disease.
|
25910410 |
2015 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, SEMA3C-targeted siRNA may be of potential use for the early diagnosis and treatment of breast cancer.
|
29113226 |
2017 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In order to examine the effects of full-length sema3C on tumor progression, we therefore generated an active point mutated furin cleavage-resistant sema3C (FR-sema3C).
|
25808871 |
2015 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Despite numerous findings that implicate SEMA3C in cancer progression, regulatory mechanisms governing its expression remain largely unknown.
|
28038451 |
2017 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Notably, some semaphorins such as sema3C and sema3E have also been found to potentiate tumor progression using various mechanisms.
|
30696103 |
2019 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Semaphorin 3C is positively expressed in gastric cancer cells and may be involved in tumor progression, presumably through the stimulation of angiogenesis.
|
22924992 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, SEMA3C-targeted siRNA may be of potential use for the early diagnosis and treatment of breast cancer.
|
29113226 |
2017 |